Eikon Therapeutics reports EIK1001 lung cancer data with 63.1% overall response rate
Eikon Therapeutics presented updated data from its Phase 2 TeLuRide-005 trial of EIK1001 with pembrolizumab and chemotherapy at the 2026 ESMO Congress, in 72 patients with previously untreated stage 4 non-small cell lung cancer. The filing reports a 63.1% pooled objective response rate and 48.6% rate of Grade 3 or higher treatment-related adverse events, with no new financial results. The data are a clinical update that does not change the company's reported financials, but they set the outlook for its Phase 2/3 TeLuRide-008 trial, with a dose-selection interim analysis expected in the second half of 2027.
Key points
- Pooled objective response rate of 63.1% and disease control rate of 89.2% in 65 efficacy-evaluable participants, at an October 1, 2026 data cutoff
- Squamous cohort objective response rate of 72.4% and median duration of response of 12.9 months; non-squamous cohort objective response rate of 55.6%
- Grade 3 or higher treatment-related adverse events occurred in 48.6% of participants, and 6.9% discontinued treatment due to them
- Interim analysis to select the single EIK1001 dose for TeLuRide-008 is expected in the second half of 2027
The filing
Written by AI on Nov 9, 2026, 11:44 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 26, 2026.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.